Gemvax & Kael

This study tested a drug called GV1001 in 78 people with Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. Participants received daily injections of either a low dose, a higher dose, or a placebo for 6 months. The goal was to see if th…

This study looked at the long-term safety of a daily injection called GV1001 in people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. It included 67 patients who had already completed a previous GV1001 study. Researchers monitor…

This phase 2 study tested two doses of GV1001, a synthetic peptide, against a placebo in 199 people with mild to moderate Alzheimer's. The goal was to see if the drug could improve thinking and daily function over 52 weeks. Earlier lab and animal studies suggested GV1001 might pr…

This early-stage study tested the safety of a drug called GV1001 in 59 healthy adults. Participants received either a single dose or multiple doses of the drug or a placebo. The goal was to see if the drug is safe and how the body processes it, not to treat any disease. Results w…